NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 82 resultados LastUpdate Última actualización 29/11/2022 [08:38:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES

NºPublicación: WO2022246066A2 24/11/2022

Solicitante:

PREC BIOLOGICS INC [US]

Resumen de: WO2022246066A2

NEO-201 has been shown to specifically bind and kill hematological malignancy cells, e.g., acute myeloid leukemia (AML), and multiple myeloma. Diagnostic methods, therapeutic methods, and combination therapies using NEO-201 optionally in combination with another agent are described.

traducir

METHODS AND KITS FOR PREDICTING THE EFFICACY OF MIDOSTAURIN FOR THE TREATMENT OF CANCER

NºPublicación: WO2022243679A2 24/11/2022

Solicitante:

KINOMICA LTD [GB]

Resumen de: WO2022243679A2

Methods are provided for predicting the efficacy of midostaurin for the treatment of a cancer in an individual subject or a cohort of patients. The method comprises determining a phosphoproteomic and/or a proteomic signature within a sample obtained from the individual subject wherein the phosphoproteomic and/or proteomic signature provides a personalised prediction for the individual subject of the efficacy of midostaurin for treatment of cancer. This invention has utility in methods for treatment of a range of cancers including acute myeloid leukaemia (AML). Companion diagnostic kits and their use in dosage regimens for the treatment of cancer are also provided.

traducir

HTLV-1 NUCLEIC ACID LIPID PARTICLE VACCINE

NºPublicación: WO2022244801A1 24/11/2022

Solicitante:

NAT INST BIOMEDICAL INNOVATION HEALTH & NUTRITION [JP]
UNIV OF THE RYUKYUS [JP]
DAIICHI SANKYO CO LTD [JP]

Resumen de: WO2022244801A1

Provided is a vaccine for the treatment and/or prevention of infection by human T-cell leukemia virus type 1 (HTLV-1). A lipid particle of the present invention has encapsulated therein a nucleic acid that enables expression of the Tax antigen or the gp46 antigen of HTLV-1. The particle includes a lipid including a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof. In the formula: R1 and R2 independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group optionally having one or more C2-C4 alkanoyloxy groups or represents a C10-C19 alkenyl group optionally having one or more C2-C4 alkanoyloxy groups; and p represents 3 or 4.

traducir

PI3Kα SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

NºPublicación: WO2022242321A1 24/11/2022

Solicitante:

UNIV CHINA PHARMA [CN]

CN_113200969_A

Resumen de: WO2022242321A1

Disclosed are triazine ring benzoxazole compounds, a preparation method therefor and an application thereof, the structural formula of the compound being represented by formula I, or a pharmaceutically acceptable salt thereof. The present application has undergone biochemical activity testing, and said class of compounds have good inhibitory activity towards PI3Kα. Therefore, the compounds can provide effective and more selective inhibitors for the treatment of diseases regulated by PI3K, and hopefully targeted drugs for treating diseases related to the PI3K signaling pathway, such as gastric cancer, breast cancer, ovarian cancer, and leukemia, will be developed.

traducir

SYNTHETIC DIMERIC CINCHONA ALKALOIDS AGAINST CANCER

NºPublicación: US2022372029A1 24/11/2022

Solicitante:

ARES PHARMACEUTICALS LLC [US]

Resumen de: US2022372029A1

Synthetic, novel dimeric cinchona alkaloid compounds having potent cytotoxic activity against human cancer cells. The compounds are effective agents for inhibiting cellular proliferation, for example, in cancer cells. The compounds cause apoptotic cell death in and cause inhibition of clonogenic growth of human breast cancer, prostate cancer, leukemia, lymphoma cells at nanomolar concentrations. The chemical structure of the compound includes dimeric cinchona alkaloid and derivatives containing various groups attached in their structure. The compounds also possess hydroxy group functionality in the structure to enable the preparation of pharmaceutically applicable salts to enhance their solubility for ease of systemic administration in animals and in humans, for example, in cancer patients.

traducir

B-LYMPHOCYTE SPECIFIC AMATOXIN ANTIBODY CONJUGATES

NºPublicación: US2022370632A1 24/11/2022

Solicitante:

HEIDELBERG PHARMA RES GMBH [DE]

WO_2022194988_PA

Resumen de: US2022370632A1

The present application relates to conjugates comprising an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking said amatoxin and said CD37-binding moiety. The invention further relates to the synthesis of said conjugates. In addition, the invention relates to a pharmaceutical composition comprising such conjugate for use in the treatment of immune cell-, particularly B-cell and/or lymphoma associated diseases and/or malignancies.

traducir

OPHTHALMIC FORMULATIONS OF METHOTREXATE

NºPublicación: US2022370460A1 24/11/2022

Solicitante:

ALDEYRA THERAPEUTICS INC [US]

JP_2022548226_A

Resumen de: US2022370460A1

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

traducir

VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINE

NºPublicación: US2022370481A1 24/11/2022

Solicitante:

ABBVIE INC [US]

Resumen de: US2022370481A1

The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine and a CYP3A inhibitor for treating myelodysplastic syndromes (MDS).

traducir

METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

NºPublicación: US2022373550A1 24/11/2022

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: US2022373550A1

Methods of monitoring progression of multiple myeloma or plasmacytoma, particularly relapsed or refractory multiple myeloma, are described. Also described are methods of treating or determining response to a treatment for multiple myeloma or plasmacytoma in a subject.

traducir

HCK DEGRADERS AND USES THEREOF

NºPublicación: US2022372017A1 24/11/2022

Solicitante:

DANA FARBER CANCER INST INC [US]

CA_3143508_PA

Resumen de: US2022372017A1

Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a kinase (e.g., HCK, BTK) to induce degradation of the kinase (e.g., HCK, BTK). Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., non-Hodgkin's lymphoma, Burkitt's lymphoma, Waldenstrom macroglobulinemia, MYD88-mutated Waldenstrom macroglobulinemia, activated B-cell diffuse large B-cell lymphoma, leukemia)), inflammatory disease, or other diseases associated with MYD88 mutations). Provided also are methods of inducing the degradation of a kinase (e.g., HCK, BTK) in a cell in a biological sample or subject by administering the bifunctional compound or composition described herein.

traducir

USE OF 1-4-BROMO-5-1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL-2-FLUOROPHENYL-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

NºPublicación: US2022370423A1 24/11/2022

Solicitante:

DECIPHERA PHARMACEUTICALS LLC [US]

US_2022370424_PA

Resumen de: US2022370423A1

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.

traducir

USE OF 1-4-BROMO-5-1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL-2-FLUOROPHENYL-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA

NºPublicación: US2022370424A1 24/11/2022

Solicitante:

DECIPHERA PHARMACEUTICALS LLC [US]

US_2022370423_PA

Resumen de: US2022370424A1

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1, 6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.

traducir

Compositions and methods for treating hematologic cancers targeting the SIRPa-CD47 interaction

NºPublicación: AU2022256193A1 24/11/2022

Solicitante:

HOSPITAL FOR SICK CHILDREN [CA]
UNIV HEALTH NETWORK [CA]

AU_2020220183_A1

Resumen de: AU2022256193A1

The invention relates to modulating the SIRPa - CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRPc polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.

traducir

PROMOTER HAVING HIGH ACTIVITY IN ACTIVATED T-CELL

NºPublicación: US2022372481A1 24/11/2022

Solicitante:

SHANGHAI CELL THERAPY GROUP CO LTD [CN]

EP_4060042_A1

Resumen de: US2022372481A1

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5′-end to 3′-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

traducir

Bispecific antibodies against CD3 and CD20

NºPublicación: AU2021267402A1 24/11/2022

Solicitante:

GENMAB AS

US_2021371538_A1

Resumen de: AU2021267402A1

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

traducir

MIR-142 COMPOUNDS AND USES THEREOF

NºPublicación: WO2022245980A1 24/11/2022

Solicitante:

HOPE CITY [US]

Resumen de: WO2022245980A1

The disclosure provides, inter alia, compounds comprising Toll-like receptor 9-binding nucleic acid sequences and nucleic acid sequences comprising a microRNA-142 passenger strand sequence hybridized to a microRNA-142 guide strand sequence; pharmaceutical compositions comprising the compounds; and the use of the compounds and pharmaceutical compositions to treat myeloid leukemia.

traducir

HUMANIZED ANTIBODIES SPECIFIC FOR MYELOMA AND OVARIAN CANCER CELLS

NºPublicación: EP4090433A1 23/11/2022

Solicitante:

CAERUS THERAPEUTICS INC [US]

KR_20220129044_A

Resumen de: WO2021146413A1

The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.

traducir

CRYSTAL FORM OF POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR

NºPublicación: EP4092021A1 23/11/2022

Solicitante:

SHANDONG XUANZHU PHARMA CO LTD [CN]
XUANZHU BIOPHARMACEUTICAL CO LTD [CN]

KR_20220143666_PA

Resumen de: EP4092021A1

The present invention relates to a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and use of the crystal form or the pharmaceutical composition. Specifically, the present invention relates to a crystal form of a compound, i.e., 5-chloro-N<4>-(2-(isopropylsulfonyl)phenyl)-N<2>-(7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)pyrimidine-2,4-diamine, that is represented by formula (1) and serves as an anaplastic lymphoma kinase inhibitor, a preparation method therefor, a pharmaceutical composition comprising the crystal form, and the use of the crystal form or the pharmaceutical composition in a medication for preventing and/or treating an anaplastic lymphoma kinase-mediated cancer or a non-cancer related disease.

traducir

COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA

NºPublicación: EP4090335A1 23/11/2022

Solicitante:

NOVARTIS AG [CH]

KR_20220128389_A

Resumen de: WO2021144657A1

Combination therapies comprising TIM-3 inhibitors are disclosed. The combinations can be used to treat cancerous conditions and disorders, including hematologic cancers.

traducir

METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA

NºPublicación: WO2022241446A1 17/11/2022

Solicitante:

GENENTECH INC [US]

Resumen de: WO2022241446A1

Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma "DLBCL") using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

traducir

C-LINKED INHIBITORS OF ENL/AF9 YEATS

NºPublicación: WO2022240830A1 17/11/2022

Solicitante:

BRIDGE MEDICINES [US]

Resumen de: WO2022240830A1

Compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are disclosed. Methods for treating acute leukemias using the compounds of Formula I and pharmaceutical compositions comprising the same are also disclosed.

traducir

NAMPT INHBITORS AND USES THEREOF

NºPublicación: WO2022241257A1 17/11/2022

Solicitante:

REMEDY PLAN INC [US]

Resumen de: WO2022241257A1

Disclosed are compounds, methods, compositions, uses, and kits that modulate (e.g., inhibit) nicotinamide phosphoribosyltransferase (NAMPT), the production of nicotinamide mononucleotide (NMN), the production of nicotinamide adenine dinucleotide (NAD), NAMPT signaling, a NAMPT pathway, and/or cellular metabolism. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Further provided are methods of manufacturing compounds of Formula (V). The compounds of the disclosure are of Formula (I), (II), (III), and (IV):

traducir

SUBSTITUTED SPIRO DERIVATIVES

NºPublicación: WO2022237627A1 17/11/2022

Solicitante:

JANSSEN PHARMACEUTICA NV [BE]
JOHNSON & JOHNSON CHINA INVEST LTD [CN]

Resumen de: WO2022237627A1

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

traducir

SUBSTITUTED SPIRO DERIVATIVES

NºPublicación: WO2022237626A1 17/11/2022

Solicitante:

JANSSEN PHARMACEUTICA NV [BE]
JOHNSON & JOHNSON CHINA INVEST LTD [CN]

Resumen de: WO2022237626A1

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

traducir

PREPARATION AND APPLICATION OF SHP2 PHOSPHATASE INHIBITOR

Nº publicación: WO2022237676A1 17/11/2022

Solicitante:

YA THERAPEUTICS INC [CN]

Resumen de: WO2022237676A1

Disclosed in the present invention are a SHP2 phosphatase inhibitor and an application thereof. Specifically, the present invention relates to a compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and an application of the compound as a protein tyrosine phosphatase SHP2 inhibitor in a medication for treatment of leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, pancreatic cancer, head and neck squamous cell carcinoma, gastric cancer, liver cancer, anaplastic large cell lymphoma, and glioblastoma, wherein definitions of the substituents in the formula (I) are the same as those in the description.

traducir

Página1 de 4 nextPage por página

punteroimgVolver